GlassScriptPhysician profile
Arvind K Wadhwa
NPI 1629077391
$7,345.88
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,177 · 2020: $1,592 · 2021: $2,046 · 2022: $1,457 · 2023: $73.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $73.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $73.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,441.30 | 2019-2023 | Stiolto Respimat |
| Lilly USA, LLC | $853.13 | 2019-2023 | Mounjaro, Emgality, Jardiance |
| Astrazeneca Pharmaceuticals LP | $718.77 | 2019-2022 | |
| Glaxosmithkline, LLC. | $658.07 | 2019-2022 | |
| Pfizer INC. | $490.54 | 2019-2022 | |
| Novo Nordisk INC | $433.43 | 2019-2023 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $307.02 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $289.71 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $250.93 | 2019-2022 | |
| Amgen INC. | $242.32 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $232.37 | 2019-2021 | |
| Astellas Pharma US INC | $211.34 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $188.19 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $144.20 | 2019-2021 | |
| Amarin Pharma, INC. | $142.36 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $125.45 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $116.65 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $99.47 | 2021 | |
| Abbott Laboratories | $59.69 | 2022 | |
| Gilead Sciences, INC. | $55.30 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $46.44 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $44.81 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $37.24 | 2020 | |
| Alexion Pharmaceuticals, INC. | $22.03 | 2020 | |
| Acadia Pharmaceuticals INC | $21.12 | 2022 | |
| Eisai INC. | $18.16 | 2022 | |
| Abbvie INC. | $17.79 | 2021 | |
| Allergan, INC. | $16.99 | 2019 | |
| Daiichi Sankyo INC. | $16.49 | 2022 | |
| Biogen, INC. | $16.02 | 2021 | |
| Scilex Pharmaceuticals INC. | $15.35 | 2019 | |
| Vanda Pharmaceuticals INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Wadhwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.